ASCO 2014 Focus on Prostate Cancer - Conference Review

In this Issue:

OS with chemohormonal vs hormonal therapy in hormone sensitive mPC
Enzalutamide in mCRPC: PREVAIL study results
Abiraterone in mCRPC: validation of a prognostic model
Abiraterone in mCRPC: population-based analysis of a novel prognostic model
AR amplification in mCRPC refractory to abiraterone or enzalutamide
Functional imaging in mCRPC
Genomic analysis of CT-DNA in abiraterone- & enzalutamide treated mCRPC
CTCs and LDH as prognostic factors in mCRPC with progression
Prognostic value of CTCs & miRNAs vs PSA in mCRPC
ARN-509 in patients with mCRPC ± prior abiraterone
Galeterone in CRPC: ARMOR2 study populations
Dose finding study of cabozantinib + abiraterone in CRPC

Please login below to download this issue (PDF)

Subscribe